ACS Medicinal Chemistry Letters

Letter

Original Design of Fluorescent Ligands by Fusing BODIPY and Melatonin Neurohormone

Jérémy Thireau,[†] Justine Marteaux,[†] Philippe Delagrange,[‡] Francois Lefoulon,[§] Laurence Dufourny,^{||} Gérald Guillaumet,[†] and Franck Suzenet^{*,†}

[†]Université d'Orléans, CNRS, ICOA, UMR 7311, F-45067 Orleans, France


[‡]Unité de Recherches et Découvertes en Neurosciences, Institut de Recherches Servier, 78290 Croissy-sur-Seine, France

[§]Technologie SERVIER, 27 rue Eugéne Vignat, 45000 Orléans, France

^{II}UMR INRA-CNRS 7247-Univ. Tours-IFCE, PRC, Centre INRA de Tours, 37380 Nouzilly, France

(5) Supporting Information

ABSTRACT: An original design and synthesis of fluorescent ligands for melatonin receptor studies is presented and consists in the fusion of the endogenous ligand with the fluorescent BODIPY core. Probes I-IV show high affinities for MT_1 and MT_2 melatonin receptors and exhibit fluorescence properties compatible with cell observation.



KEYWORDS: GPCRs, melatonin, fluorescence, molecular probes, BODIPY

F luorescence is one of the most sensitive spectroscopic methods and many fluorescent ligands have been reported for locating G-protein-coupled receptors (GPCRs), for studying ligand/receptor interactions, and more generally for better understanding their pharmacology and physiological process.¹⁻⁴ The history of fluorescent ligands is linked to the development of commercially available fluorophores. Organic dyes have been designed and synthesized to exhibit excitation and emission wavelengths, which are compatible with biological observation and are associated to ligands in conjugation reactions. The addition of such a distinct fluorescent molecule may alter both the chemical (while remaining within a spectrum of lipophilicity to hydrophilicity) and pharmacological (affinity, functionality, etc.) properties of the resulting fluorescent ligand that will modify its cellular behavior.

The melatonin receptors MT_1 and MT_2 are members of the GPCR family. They are involved in the regulation of the circadian rhythm and seasonal functions in mammals. They are also implicated in many biological processes ranging from antiinflammatory to antioxidant effects including anti-Parkinson effects^{5,6} and were recently reported as part of the mechanism of action of the antidepressant agomelatine, an MT_1 and MT_2 receptor agonist and 5-HT_{2C} antagonist.^{7,8} Despite the discovery of the high affinity agonist and nonselective 2-[¹²⁵I]-MLT radioligand⁹ research on the pharmacology and the functionality/physiological impact of melatonin receptors suffers from the lack of selective probes for these receptors due to their very low level of expression. Moreover, the main disadvantages of this method are the radioactive hazards and the limitations of studying the molecular dynamics of receptor activation. To offer alternative probes, we have developed a concept aiming at using the aromatic core of an endogenous ligand as the source of fluorescence after slight chemical modification and without loss of biological activity. Herein, we report the design and synthesis of fluorescent ligands for melatonin receptor studies thanks to the fusion of the endogenous ligand with the fluorescent BODIPY core.

Melatonin presents in its chemical structure an indole ring possessing fluorescent properties that are unfortunately inappropriate for biological analysis due to interferences from other biochromophores (such as tryptophan).^{10,11} Our expertise on the melatonin structure/activity relationship^{12–16} prompts us to investigate the extension of the π -conjugation of the indole scaffold at position C-2 in order to obtain biologically compatible photophysical properties. The original idea consists in the fusion of the pyrrole ring of melatonin with one of the pyrrole rings of the highly stable and bright difluoroboraindacene (BODIPY) fluorophore^{17–19} (Figure 1). The fluorescence of the resulting indole-based BODIPY was expected as recently described by Zhao, Zhu, and coworkers.^{20,21}

To attempt the fused melatonin-BODIPY core, 2-iodomelatonin 1,^{22–24} was converted into 2-formylmelatonin 2 by a palladium catalyzed carbonylative coupling reaction in the presence of tributyltin hydride in good yields using the Fukuyama procedure.²⁵ Condensation of the pyrroles with 2

Received: October 15, 2013 Accepted: November 20, 2013





Figure 1. Fused melatonin-BODIPY.

Bodipy Con

under traditional experimental conditions using acidic catalyst (POCl₃, HBr) was unable to furnish the desired product. Considering the final difluoroborane complex, we envisaged the direct activation of the carbonyl function in compound **2** with boron trifluoroborate etherate.²⁶ The Lewis acid was added slowly at low temperature to the solution of 2-formylmelatonin **2**, and after 15 min the pyrrole was added. Synthesis of the final boron complex was achieved by adding triethylamine with six extra equivalents of BF₃·Et₂O. The first two desired structures **I** and **II** were isolated in 21% and 24% yield, respectively (Scheme 1).

Scheme 1. Synthetic Pathway to Molecules I and II




Accentuation of the conjugation in BODIPY is known to induce a red-shift in the excitation and emission wavelengths, which is more compatible for biological observations.^{17–19,27,28} Such a π extension can be performed by introducing an aryl or a hetaryl group at the 3 and/or 5 positions of the pyrrole moiety using metal catalyzed reactions,^{29–32} the Knoevenagel reaction,^{33,34} vicarious nucleophilic substitution (VNS),³⁵ or by modifying the substituents linked to the boron atom.³⁶ For our purpose, aryl and styryl groups were envisaged and pyrroles 3 and 4 were first synthesized. Condensation with 2-formylmelatonin according to the previous protocol finally afforded the desired boron complexes III and IV with extended π -delocalization in 35 and 37% yield, respectively (Scheme 2).

The photophysical properties of these new dyes were measured in dimethylsulfoxide. Absorption (Figure 2) and molar extinction coefficients of compounds I-IV are reported in Table 1.

All four boron complexes show fluorescent properties. The emission spectra (Figure 3) for I and II are around 490–540

IV. 37%



Scheme 2. Synthetic Pathway to Molecules III and IV

Figure 2. Normalized absorption of compounds I (green), II (blue), III (red), and IV (purple) in DMSO.

Table 1. Absorption Wavelengths and Molar Extinction Coefficients of Compounds I–IV in DMSO




Figure 3. Normalized fluorescence emission spectra properties of compounds I (green), II (blue), III (red), and IV (purple) in DMSO (for λ_{exc} , see Table 2).

nm. Compounds III and IV, with extra π -conjugation, show excitation and emission bands at lower energy as expected. These new indole-based BODIPYs present Stokes shifts between 21 and 111 nm comparable with standard BODIPY dye values.^{17–19}

The binding affinities of the four fluorescent derivatives I-IV were evaluated (Table 3) on human MT_1 and MT_2 receptors. They all show good affinities: ligands I and IV present affinities in the range of tens of nanomolar concentrations for the two

ACS Medicinal Chemistry Letters

Table 2. Photophysical Properties of Compounds I–IV in DMSO

compd	Ι	II	III	IV
$\lambda_{\rm exc} (\rm nm)$	426	424	573	583
$\lambda_{\rm em}~({\rm nm})$	493	535	616	604
Stokes shift (nm)	67	111	43	21

Table 3. Binding Affinity of Compounds I–IV on Human MT_1 and MT_2 Receptors

compd	$MT_1 K_i \pm SEM (nM)$	$MT_2 K_i \pm SEM (nM)$
Ι	32 ± 5	10 ± 0.7
п	256 ± 40	96 ± 20
III	49 ± 15	315 ± 9
IV	71 ± 15	26 ± 1

receptors, while ligand II is more selective for the MT_2 receptor, and ligand III displays a larger MT_1 receptor selectivity.

In conclusion, by fusing the endogenous ligand of melatonin receptors with the well-known and efficient fluorescent BODIPY core, we have been able to design and isolate four new condensed fluorescent probes with good melatonin receptor affinities. Extension of the π -conjugation of ligands I and II by coupling with an aryl (ligand III) or a styryl group (ligand IV) induces a bathochromic shift with slight impact on the affinity. Cellular imaging studies are currently under way.

ASSOCIATED CONTENT

S Supporting Information

Experimental details for the synthesis and the characterization of ligand I-IV and intermediates, spectroscopic data, and pharmacology. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*(F.S.) Tel: + 33 (0) 2 38 49 45 80. Fax: + 33 (0)2 38 41 72 81. E-mail: franck.suzenet@univ-orleans.fr.

Funding

This work was supported by La Région Centre (APR2009-LOIREMEL). During this study, J.T. and J.M. were supported (Ph.D grants) by the Conseil Général du Loiret (J.T.) and La Région Centre (J.M., APR2012-LIFERMEL)

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The authors would like to thank Dr. S. Poupart for her advice.

REFERENCES

(1) Kuder, K.; Kieć-Kononowicz, K. Fluorescent GPCR Ligands as New Tools in Pharmacology. *Curr. Med. Chem.* 2008, *15*, 2132–2143.

(2) Böhme, I.; Beck-Sickinger, A. G. Illuminating the Life of GPCRs. *Cell Commun. Signal* **2009**, *7*, 16.

(3) Goddard, A. D.; Watts, A. Contributions of Fluorescence Techniques to Understanding G Protein-Coupled Receptor Dimerisation. *Biophys. Rev.* **2012**, *4*, 291–298.

(4) Jakobs, D.; Sorkalla, T.; Häberlein, H. Ligands for Fluorescence Correlation Spectroscopy on g Protein-Coupled Receptors. *Curr. Med. Chem.* **2012**, *19*, 4722–4730.

(5) Genovese, T.; Mazzon, E.; Muià, C.; Bramanti, P.; De Sarro, A.; Cuzzocrea, S. Attenuation in the Evolution of Experimental Spinal Cord Trauma by Treatment with Melatonin. J. Pineal Res. 2005, 38, 198–208.

(6) Delagrange, P.; Atkinson, J.; Boutin, J. A.; Casteilla, L.; Lesieur, D.; Misslin, R.; Pellissier, S.; Pénicaud, L.; Renard, P. Therapeutic Perspectives for Melatonin Agonists and Antagonists. *J. Neuro-endocrinol.* **2003**, *15*, 442–448.

(7) De Bodinat, C.; Guardiola-Lemaitre, B.; Mocaër, E.; Renard, P.; Muñoz, C.; Millan, M. J. Agomelatine, the First Melatonergic Antidepressant: Discovery, Characterization and Development. *Nature Rev. Drug Discovery* **2010**, *9*, 628–642.

(8) Spadoni, G.; Bedini, A.; Rivara, S.; Mor, M. Melatonin Receptor Agonists: New Options for Insomnia and Depression Treatment. CNS Neurosci. Ther. **2011**, *17*, 733–741.

(9) Vakkuri, O.; Lämsä, E.; Rahkamaa, E.; Ruotsalainen, H.; Leppäluoto, J. Iodinated Melatonin: Preparation and Characterization of the Molecular Structure by Mass and 1H NMR Spectroscopy. *Anal. Biochem.* **1984**, *142*, 284–289.

(10) Wu, P.-W.; Hsieh, W.-T.; Cheng, Y.-M.; Wei, C.-Y.; Chou, P.-T. Synthesis of 7-Azaserotonin: Its Photophysical Properties Associated with Excited State Proton Transfer Reaction. *J. Am. Chem. Soc.* **2006**, *128*, 14426–144327.

(11) Wu, P.-W.; Cheng, Y.-M.; Hsieh, W.-T.; Wang, Y.-H.; Wei, C.-Y.; Chou, P.-T. 7-Azamelatonin: Efficient Synthetic Routes, Excitedstate Double Proton Transfer Properties and Biomedical Implications. *ChemMedChem* **2007**, *2*, 1071–1075.

(12) Legros, C.; Matthey, U.; Grelak, T.; Pedragona-Moreau, S.; Hassler, W.; Yous, S.; Thomas, E.; Suzenet, F.; Folleas, B.; Lefoulon, F.; Berthelot, P.; Caignard, D.-H.; Guillaumet, G.; Delagrange, P.; Brayer, J.-L.; Nosjean, O.; Boutin, J. A. New Radioligands for Describing the Molecular Pharmacology of MT_1 and MT_2 Melatonin Receptors. Int. J. Mol. Sci. 2013, 14, 8948–8962.

(13) Jeanty, M.; Suzenet, F.; Delagrange, P.; Nosjean, O.; Boutin, J. A.; Caignard, D. H.; Guillaumet, G. Design and Synthesis of 1-(2-Alkanamidoethyl)-6-methoxy-7-azaindole Derivatives as Potent Melatonin Agonists. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2316–2319.

(14) El Kazzouli, S.; Griffon du Bellay, A.; Berteina-Raboin, S.; Delagrange, P.; Caignard, D.-H.; Guillaumet, G. Design and Synthesis of 2-Phenylimidazo[1,2-a]pyridines as a Novel Class of Melatonin Receptor Ligands. *Eur. J. Med. Chem.* **2011**, *46*, 4252–4257.

(15) Suzenet, F.; Guillaumet, G.; Jeanty, M.; Delagrange, P.; Caignard, D.-H.; Spedding, M. Derives Indoles, leur Procede de Preparation et les Compositions Pharamaceutiques qui les Contiennent. WO2010061074A1, 2010.

(16) Jeanty, M.; Blu, J.; Suzenet, F.; Guillaumet, G. Synthesis of 4and 6-Azaindoles via the Fischer Reaction. *Org. Lett.* **2009**, *11*, 5142– 5145.

(17) Loudet, A.; Burgess, K. BODIPY Dyes and Their Derivatives: Syntheses and Spectroscopic Properties. *Chem. Rev.* **200**7, *107*, 4891–4932.

(18) Ulrich, G.; Ziessel, R.; Harriman, A. The Chemistry of Fluorescent BODIPY Dyes: Versatility Unsurpassed. *Angew. Chem., Int. Ed.* **2008**, *47*, 1184–1201.

(19) Boens, N.; Leen, V.; Dehaen, W. Fluorescent Indicators Based on BODIPY. *Chem. Soc. Rev.* 2012, *41*, 1130–1172.

(20) Zhao, C.; Zhou, Y.; Lin, Q.; Zhu, L.; Feng, P.; Zhang, Y.; Cao, J. Development of an Indole-Based Boron-Dipyrromethene Fluorescent Probe for Benzenethiols. *J. Phys. Chem. B* **2011**, *115*, 642–647.

(21) Zhao, C.; Feng, P.; Cao, J.; Zhang, Y.; Wang, X.; Yang, Y.; Zhang, Y.; Zhang, J. 6-Hydroxyindole-based Borondipyrromethene: Synthesis and Spectroscopic Studies. *Org. Biomol. Chem.* **2012**, *10*, 267–272.

(22) Franschini, F.; Stankov, B.; Di Bella, L.; Duranti, E.; Lagguzzi, A. Contraceptive And Menstrual Cycle Controlling Drug Having Oncostatic Properties. EP0483077A2, 1992.

(23) Leclerc, V.; Yous, S.; Delagrange, P.; Boutin, J. A.; Renard, P.; Lesieur, D. Synthesis of Nitroindole Derivatives with High Affinity and Selectivity for Melatoninergic Binding Sites MT₃. *J. Med. Chem.* **2002**, 45, 1853–1859.

ACS Medicinal Chemistry Letters

(24) Baran, P. S.; Shenvi, R. A. Total Synthesis of (±)-Chartelline C. J. Am. Chem. Soc. **2006**, 128, 14028–14029.

(25) Tokuyama, H.; Kaburagi, Y.; Chen, X.; Fukuyama, T. Synthesis of 2,3-Disubstituted Indoles by Palladium-Mediated Coupling of 2-Iodoindoles. *Synthesis* **2000**, 429–434.

(26) Li, Z.; Mintzer, E.; Bittman, R. First Synthesis of Free Cholesterol-BODIPY Conjugates. J. Org. Chem. 2006, 71, 1718–1721.

(27) Dost, Z.; Atilgan, S.; Akkaya, E. U. Distyryl-Boradiazaindacenes: Facile Synthesis of Novel Near IR Emitting Fluorophores. *Tetrahedron* **2006**, *62*, 8484–8488.

(28) Baruah, M.; Qin, W.; Flors, C.; Hofkens, J.; Vallée, R. A. L.; Beljonne, D.; Van der Auweraer, M.; De Borggraeve, W. M.; Boens, N. Solvent and pH Dependent Fluorescent Properties of a Dimethylaminostyryl Borondipyrromethene Dye in Solution. *J. Phys. Chem. A* **2006**, *110*, 5998–6009.

(29) Rohand, T.; Qin, W.; Boens, N.; Dehaen, W. Palladium-Catalyzed Coupling Reactions for the Functionalization of BODIPY Dyes with Fluorescence Spanning the Visible Spectrum. *Eur. J. Org. Chem.* **2006**, *20*, 4658–4663.

(30) Cho, D. W.; Fujitsuka, M.; Ryu, J. H.; Lee, M. H.; Kim, H. K.; Majima, T.; Im, C. S2 Emission from Chemically Modified BODIPYs. *Chem. Commun.* **2012**, *48*, 3424–3426.

(31) Chen, J.; Mizumura, M.; Shinokubo, H.; Osuka, A. Functionalization of Boron Dipyrrin (BODIPY) Dyes Through Iridium and Rhodium Catalysis: a Complementary Approach to Alpha- and Beta-substituted BODIPYs. *Chem.—Eur. J.* **2009**, *15*, 5942–5949.

(32) Han, J.; Gonzalez, O.; Aguilar-Aguilar, A.; Peña-Cabrera, E.; Burgess, K. 3- and 5-Functionalized BODIPYs via the Liebeskind–Srogl Reaction. *Org. Biomol. Chem.* **2009**, *7*, 34–36.

(33) Bura, T.; Hablot, D.; Ziessel, R. Fluorescent Boron Dipyrromethene (BODIPY) Dyes Having Two and Four Vinyl Residues. *Tetrahedron Lett.* **2011**, *52*, 2370–2374.

(34) Niu, S. L.; Massif, C.; Ulrich, G.; Ziessel, R.; Renard, P.-Y.; Romieu, A. Water-Solubilisation and Bio-Conjugation of a Red-Emitting BODIPY Marker. *Org. Biomol. Chem.* **2011**, *9*, 66–69.

(35) Leen, V.; Van der Auweraer, M.; Boens, N.; Dehaen, W. Vicarious Nucleophilic Substitution of A-hydrogen of BODIPY and Its Extension to Direct Ethenylation. *Org. Lett.* **2011**, *13*, 1470–1473.

(36) Goze, C.; Ulrich, G.; Mallon, L. J.; Allen, B. D.; Harriman, A.; Ziessel, R. Synthesis and Photophysical Properties of Borondipyrromethene Dyes Bearing Aryl Substituents at the Boron Center. J. Am. Chem. Soc. 2006, 128, 10231–10239.